Bristol-Myers Squibb Taps Cravath for ImClone Deal

August 1, 2008 Cravath, Swaine & Moore is advising Bristol-Myers Squibb on the planned acquisition of the rest of ImClone Systems, the maker of the best-selling cancer drug Erbitux, for $4.5 billion.

Corporate partner Allen Finkelson is leading the Cravath team, which includes corporate partners Thomas Dunn and Susan Webster, and tax partners Stephen Gordon and Lauren Angelilli.

Read more at amlawdaily.typepad.com.

comments powered by Disqus